Correction Open Access
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2025; 16(8): 107778
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.107778
Correction to “Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/ β-catenin in urinary bladder cancer patients”
Niharika Maurya, Rinni Singh, Minal Garg, Department of Biochemistry, University of Lucknow, Lucknow 226007, India
Apul Goel, Department of Urology, King George's Medical University, Lucknow 226003, India
Atin Singhai, Department of Pathology, King George's Medical University, Lucknow 226003, India
Uday Pratap Singh, Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226014, India
Vinita Agrawal, Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India
ORCID number: Niharika Maurya (0000-0003-1433-3474); Rinni Singh (0000-0003-4116-8152); Apul Goel (0000-0002-5813-3012); Atin Singhai (0000-0001-8018-0723); Uday Pratap Singh (0000-0003-3353-9697); Vinita Agrawal (0000-0003-1806-7142).
Author contributions: All authors contributed to this paper, and all the authors have agreed with the submission in its present form.
Conflict-of-interest statement: All the authors of the study declare no potential conflict-of-interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rinni Singh, PhD, Department of Biochemistry, Lucknow University, University Road, Lucknow 226007, India. singhrinni7@gmail.com
Received: May 9, 2025
Revised: May 30, 2025
Accepted: July 2, 2025
Published online: August 24, 2025
Processing time: 144 Days and 21.7 Hours

Abstract

Correction to “Maurya N, Singh R, Goel A, Singhai A, Singh UP, Agrawal V, Garg M. Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/ β-catenin in urinary bladder cancer patients. World J Clin Oncol 2019; 10(4): 166-182 [PMID: 31114749 DOI: 10.5306/wjco.v10.i4.166]”. In this article, a correction note is to be added.

Key Words: World Journal of Clinical Oncology; Correction

Core Tip: This manuscript is to add a “correction note” to “Maurya N, Singh R, Goel A, Singhai A, Singh UP, Agrawal V, Garg M. Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/ β-catenin in urinary bladder cancer patients. World J Clin Oncol 2019; 10(4): 166-182 [PMID: 31114749 DOI: 10.5306/wjco.v10.i4.166]”.
CORRECTION

Correction to: Maurya N, Singh R, Goel A, Singhai A, Singh UP, Agrawal V, Garg M. Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/ β-catenin in urinary bladder cancer patients. World J Clin Oncol 2019 Apr 24; 10(4): 166-182.

In this article, a correction note is to be added[1]. We would like to clarify that the purpose of this correction is solely to replace the image in concern as brought to notice by the Editorial Office via email dated January 22, 2024. The correction does not alter the study's original findings, conclusions, or interpretations. It is an earnest request that please incorporate the following correction note and unpublished raw images in place of the concerned image and publish a correction regarding the same.

The concerned IHC images in figure 3 have been replaced with other raw unpublished images (Figure 1).

Figure 1
Open in New Tab   Full Size Figure   Download Figure
Figure 1 The other raw unpublished images. A: Positive control for pS9GSK-3β showing strong membranous expression in normal urothelium (replace figure 3A, a); B: Cyclin D1 nuclear immunoexpression in 60%-70% (replace figure 3B, h); C: 100% nuclear staining for Cyclin D1 in urothelium (replace figure 3C, m).
Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: India

Peer-review report’s classification

Scientific Quality: Grade B, Grade B, Grade C

Novelty: Grade B, Grade D, Grade D

Creativity or Innovation: Grade B, Grade C, Grade D

Scientific Significance: Grade B, Grade C, Grade C

P-Reviewer: Beker S; Budaya TN; Rath S S-Editor: Li L L-Editor: A P-Editor: Zhang XD

References
1.  Maurya N, Singh R, Goel A, Singhai A, Singh UP, Agrawal V, Garg M. Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/ β-catenin in urinary bladder cancer patients. World J Clin Oncol. 2019;10:166-182.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 2]  [Cited by in RCA: 4]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]